Vanguard Capital Management
NGNE icon

Vanguard Capital Management’s Neurogene NGNE Stock Holding History

Vanguard Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
536,525
+21,798
+4% +$600K ﹤0.01% 2540
2026
Q1 		$10.4M Buy
+514,727
New +$9.97M ﹤0.01% 2714

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Capital Management's NGNE Position: Q2 2026 in Review

Vanguard Capital Management increased its Neurogene (NGNE) stake by 4.2% in Q2 2026, buying an estimated $600K and bringing the position to 536,525 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2540.

Vanguard Capital Management first reported a position in NGNE in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Vanguard Capital Management held 536,525 shares of Neurogene worth $16.9M as of Q2 2026.
  • Vanguard Capital Management bought 21,798 Neurogene shares in Q2 2026, an estimated $600K.
  • Neurogene made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2540 holding.
  • Vanguard Capital Management first reported a position in Neurogene in Q1 2026 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.